Therefore, this investigation of the mechanism underlying SLC34A2 in CRC sheds new light on development of potential therapeutics against CRC via targetting SLC34A2-ROS-HIF-1- EZH2 signaling pathway. The gene discussed is SETD2; the disease is colorectal carcinoma.